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Summary Spontaneously transformed somatic thyrocyte mutants, FRTL-5/TA and FRTL-5/TP, are
thyrotropin (TSH) independent for growth and show loss of the thyroid-specific phenotype, with absent
thyroglobulin and thyroid peroxidase gene expression. To investigate the role of TSH-receptor (TSH-R)
activation in rat thyroid growth and function, binding of TSH and TSH-induced cAMP production were
measured in intact cells under identical assay conditions. TSH binding did not differ in terms of affinity and
receptor number and presence of 5.6 kb and 3.3 kb mRNA rat TSH-R transcripts was determined in all
variants. By contrast, basal cAMP was I1-fold lower in FRTL-5/TA and 6-fold lower in FRTL-5/TP than in
wild-type FRTL-5 (1.1+0.4; P<0.01). Maximal cAMP production was similar between wild-type and cell
variants and stimulation by bovine, rat and recombinant human TSH revealed normal activation patterns.
Therefore, a dissociation was present between the loss of TSH control on growth and function, and the
presence of a normally functioning TSH-R. Subsequent to TSH incubation FRTL-5/TP and FRTL-5/TA cells
showed a different expression pattern of TSH-R and the proto oncogenes c-myc and fos than FRTL-5 wild-
type. The data indicated that the cause ofthe TSH-independency is located down-stream of the cAMP cascade,
influencing genes that control the expression of cell cycle-related proto-oncogenes and thyroid-specific genes.
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The glycoprotein hormone thyrotropin (TSH) is the major
regulator of thyroid function and growth (Vassart and
Dumont, 1992). Actions of TSH are exerted through
interaction with the plasma membrane TSH receptor (TSH-
R), which has been characterised as a member of the G-
protein coupled receptor family (Nagayama et al., 1989;
Libert et al., 1989). Following binding of TSH to the TSH-R,
G-proteins will be activated, resulting in stimulation of
adenylate cyclase (Dumont et al., 1989) and cAMP
production or in stimulation of phospholipase C with
subsequent diacylglycerol and inositol-3-phosphate produc-
tion (Vassart and Dumont, 1992). cAMP is generally
assumed to regulate a major part of thyroid function and
thyroid growth (Vassart and Dumont, 1992).
Thyroid tumours can be divided into functional and non-
functional tumours. With regard to growth and metabolic
activity, functional tumours are responsive to TSH like
normal thyroid tissue. As a tumour evolves, phenotype-
specific metabolic activities decrease or disappear (Christov
and Raichev, 1972; Wollman, 1963), as has been described in
transgenic models (Ledent et al., 1991). Non-functional
tumours show absence of phenotype-specific thyroid func-
tions and, characteristically, TSH is unable to stimulate such
functions, or growth. Therefore, loss of TSH responsiveness
could result from a TSH-R defect or a defect in a post-
receptor element important for signal transduction. For
example, absence of high-affinity TSH-R (Abe et al., 1981),
a defective coupling between the TSH-R and G-protein
(Namba et al., 1993), a TSH-R point mutation (Parma et al.,
1993), and a Gsa mutation including those found in other
endocrine tumours (Lyons et al., 1990; Yoshimoto et al.,
1993) have been suggested to explain the observed TSH
independency or TSH unresponsiveness. In experimental
terms validity of either of the first two possibilities would
be supported by findings of abnormal TSH binding or an
abnormal pattern of TSH-induced cAMP production. The
latter two possibilities are then expected to result in a higher
basal cAMP level.
In the present study we tested these possibilities
experimentally using the FRTL-5 rat thyroid cell line and
spontaneously transformed somatic cell variants with
different degrees of differentiation and sensitivity to TSH
(Ossendorp et al., 1990). FRTL-5 cells are an accepted model
for normal thyroid function as these cells show responsive-
ness to TSH for iodide uptake, thyroglobulin (Tg) iodination
and secretion, and cell growth. The variant cell lines have
been generated by subcutaneous injection of FRTL-5 cells in
nude mice. From the tumours that subsequently developed,
variant cell lines were derived as described by Ossendorp et
al. (1990). The variant cell line FRTL-5/T, isolated from a
functionally active tumour, shows normal responsiveness to
TSH for most thyroid-specific functions (Ossendorp et al.,
1990). This is in contrast to the FRTL-5/TA and FRTL-5/TP
variants, isolated from non-functional tumours, which are
insensitive to TSH with respect to iodide uptake, thyroglo-
bulin iodination and secretion, and cell growth, thus fulfilling
the criteria of somatic cell mutants with the phenotype of
autonomous TSH-independent growth and function (Ossen-
dorp et al., 1990). In the present study we evaluated whether
acquisition of autonomy was associated with defects in the
binding of the ligand, or with defects in the second messenger
system. The production of cAMP in response to TSH was
characterised under the same conditions in which TSH
binding to its receptor can be measured; binding was
evaluated in terms of capacity and affinity. In addition, the
response of the proto-oncogenes c-myc andfos was measured
to characterise the effect of TSH at the early steps of the cell
cycle.
Materials and methods
Culture of FRTL-5 cells and variant cell lines
FRTL-5, FRTL-5/T and FRTL-5/TP cells were cultured in
6H (six-hormone mixture) medium (Ambesi-Impiombato et
al., 1980) consisting of Coon's modified Ham's medium
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March 1996(Gibco BRL, Breda, The Netherlands) containing 5% fetal
calf serum (Gibco) and insulin (10 jug ml-'), hydrocortisone
(0.36 ng ml-'), transferrin (5 jug ml-1), somatostatin
(10 ng ml-'), glycyl-L-histidyl-L-lysine acetate (2 ng ml-')
(all Sigma, St Louis, MO, USA) and bTSH (bovine TSH)
100 uU ml-1 (Ambinon, Organon, Oss, The Netherlands). As
FRTL-5/TA cells were generated under TSH-free conditions,
the cells were cultured in SH (5 hormone mixture) medium
(TSH-free medium, identical to the medium described above
but without TSH) as described previously (Ossendorp et al.,
1990).
In experiments that measured cAMP production and TSH
binding, cells were cultured in six-well plates (Gibco). Five
days before the experiments, cell variants were cultured
without TSH in such a way that the cells were confluent on
the experimental day. One day before the experiments fresh
medium was added to the cells.
['25I]TSH binding and competition (whole cell assay)
The iodination of bTSH (kindly supplied by Dr JG Pierce,
University of California, CA, USA) was performed as
described by Roelen et al. (1992) for human growth
hormone. Briefly, 5 ,ug of bTSH was iodinated in a total
volume of 25 jul with 0.3 mg ml-' chloramine-T (final
concentration), the reaction was terminated with 100 Ml of
0.96 mg ml- Na-meta-bisulphite (final concentration). Free
and bound 1251 were separated on Sephadex G-25 (PD-10
columns, Pharmacia, Uppsala, Sweden). The incorporation of
1251 was 72+6.4% (mean+s.e.m., n=9). The ['251]bTSH in
the protein fraction obtained from the Sephadex G-25
column was receptor purified by binding to and elution
from porcine thyroid plasma membranes (Smith et al., 1977).
Eluates were purified on a Sephadex S-200 column with Tris
sodium chloride (10-50 mM) containing 0.1% bovine serum
albumin (BSA).
Confluent cells were washed three times with modified
Hanks' balanced salt solution (HBSS: 5 mM potassium
chloride, 1.3 mM calcium chloride, 0.4 mm magnesium
sulphate, 0.34 mM disodium hydrogen phosphate, 0.44 mM
potassium hydrogen phosphate, 280 mm sucrose and 0.25%
BSA) and incubated for 1 h at 37°C in 1 ml of HBSS
containing ['251I]bTSH (± 10 000 c.p.m. sp. act. 1.2 x
106 d.p.m. fmol-1) and various concentrations of bTSH
(1 juU=2.4 fmol), rhTSH (recombinant human TSH, Gen-
zyme, West-Malling, UK; 1 iU=4.2 fmol) and rTSH (rat
TSH, kindly provided by NIDDK, NHPP, Baltimore, MD,
USA; 1 pU= 1.0 fmol) (0-2.40, 0-0.42 and 0-0.24 jM
respectively). After 1 h the incubation buffer was removed,
cells were washed three times with ice-cold HBSS and 1 ml of
1 N sodium hydroxide was added to detach the cells. The
bound radioactivity was transferred to tubes and counted in a
y-counter. The dissociation constants (K) of bTSH and the
number of TSH binding sites (R) were calculated with a
linear subtraction method (Van Zoelen, 1989). To compare
the affinities of bTSH, rTSH and rhTSH IC50-values (50%
competition) were determined from the competition curves.
Effect of TSH on intracellular cAMP response
Confluent cells were washed three times with HBSS. The cells
were incubated at 37°C in 1 ml ofHBSS containing 0.5 mM 3-
isobutyl-l-methylxanthine (Sigma) and various concentrations
of bTSH, rhTSH, rTSH (0-0.24, 0-0.44 and 0-0.024 UM
respectively). After 1 h the incubation was terminated by
removing the buffer and addition of 1 ml of 96% ice-cold
ethanol. Cells were stored at least overnight at -20°C. Cells
were scraped with a rubber policeman, the ethanol was
evaporated at 37°C under a stream ofnitrogen and 0.5 ml of a
Tris-EDTA (50 mm, 4 mM, pH 7.5) buffer was added. After
centrifugation for 10 min at 3600 r.p.m. the supernatants were
used to measure cAMP (radioreceptor assay TRK 432,
Amersham, Little Chalfont, UK). DNA was measured in the
pellets (Burton, 1956), using calf thymus DNA (Boehringer
TSH receptor function in FRTL-5 variants
CJH van der Kallen et al 0
607
Mannheim, Mannheim, Germany) as a standard. To compare
the effects of bTSH, rTSH and rhTSH, their concentrations
yielding 50% of the maximal cAMP response (EC5o) were
calculated from the dose-response curves.
Measurements of intracellular cAMP were performed
under similar conditions that enabled assay of TSH binding
and competition. Control experiments, comparing cells of
several passages, revealed similar properties with regard to
TSH binding and cAMP response in the course of 4 years
with all variants and wild-type FRTL-5.
Detection of TSH-R, c-myc andfos RNA expression
FRTL-5 cells and variants were harvested for RNA isolation
after 7 days of TSH depletion (5H medium) or after variable
intervals following TSH stimulation (100 iU ml-'). RNA
isolation was performed as described previously (Ossendorp
et al., 1990). In short, cells were homogenised in 6 M urea/
3 M lithium chloride. After centrifugation (10 000 xg, 45 min,
4°C), the pellet was dissolved in 10 mM Tris-HCl (pH 7.6),
5 mM EDTA, 1% sodium dodecyl sulphate (SDS), deprotei-
nised by two extracts with phenol-chloroform (1:1) and
precipitated with ethanol. Samples of RNA were denatured
at 60°C for 30 min in a solution containing 50% (v/v)
formamide, 2.2 M formaldehyde and RNA running buffer
(20 mM) MOPS (pH 7.0), 5 mM sodium acetate, and 1 mM
EDTA.
For Northern analysis, RNA samples were separated by
electrophoresis in 1.0% agarose gels, followed by transfer to
nitrocellulose filters and fixed by heating (80°C for 4 h) as
described in detail (Ossendorp et al., 1990). Membranes were
hybridised with 32P-labelled probes (Ossendorp et al., 1990).
The following probes were used: cDNA clones of the c-myc
and fos genes (Tramontano et al., 1986) and a prepared
cDNA rat TSH-R insert (1039-1190) probe. The TSH-R
cDNA probe (1039-1190) was prepared by polymerase chain
reaction (PCR) of the T8AFB clone (courteously donated by
Dr Leonard Kohn, NIH, Bethesda, MD, USA) containing
the full-length rat cDNA coding sequence (-54 to 2780 bp).
For reprobing the filters were stripped by washing the filter
twice with 0.05 x SSC, 0.01 M EDTA (hot) and 0.1% SDS for
15 min and once briefly with 0.01 x SSC at room tempera-
ture.
Ethidium bromide staining of whole RNA in the agarose
gel revealed the 28S (4.8 kb) and 18S (2.0 kb) ribosomal
RNA markers respectively, which were used as a control for
application of equal amounts of RNA. Quantification of
intensity was performed by densitometer.
Statistical analysis
Results are given as means+s.e.m. (n). Significances of the
observed differences were calculated with the non-parametric
Mann-Whitney U-test. P-values <0.05 were considered to
reflect statistical significance.
Results
["25I]TSH binding and competition (whole cell assay) (Figure
1 and 2, Table I)
Total binding of ['251]bTSH to FRTL-5 cells was 8.3+1.4%
of the amount added (n=8), with a non-specific binding of
0.31 +0.12%. These values did not differ significantly
between the different cell line variants. The combined data
of the competition curves and Scatchard plot analysis of
FRTL-5 cells (n=7-8, separate experiments) are shown in
Figures la and 2. The analysis was performed both for one
and two classes of binding sites. Analysis according to a two-
class model yielded a high-affinity, low-capacity binding site
with properties similar to the results of the analysis for one
binding site. In addition, a binding site with extremely low
affinity and high capacity was detectable. As this binding site
was considered to represent non-specific binding, furtherTSH receptor function in FRTL-5 variants
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Figure 1 cAMP response to bTSH (n = 5-7) and [125I]bTSH competition curve (n =7-8) of FRTL-5 (a), FRTL-5/T (b), FRTL-5/
TP (c) and FRTL-5/TA cells (d). Cells are incubated for 1 h (HBSS) with different concentrations of bTSH. B/Bo (%) and cAMP
(%) represent the values measured relative to the maximal values; 0, TSH displacement; +, cAMP response.
Table I Capacity (R) and affinity (Kd) of bTSH binding to FRTL-5 wild type and variant cell lines
and IC50-values for the competition of [125I]bTSH by radioinert competitors
Cell line
Parameter FRTL-5 FRTL-5/T FRTL-S/TP FRTL-5/TA
(R) 134+20 (8) 259+93 (5) 127+28 (5) 102+29 (7)
Kd bTSH 1.0+0.4 (8) 2.4+0.5 (5) 1.8+0.3 (5) 2.3+0.5 (8)
IC50 bTSH 2.7+0.6a (8) 2.7+0.7a (5) 3.6+1.la (5) 3.7+0.7a (7)
IC50 rTSH 2.0+0.9a (6) 4.3+1.4 (4) 1.9+ 1.3a (3) 1.9+0.5a (4)
IC50 rhTSH 56+24 (3) 35+19 (3) 127+22b (3) 103+34 (3)
Kd and IC50 are given in nm, (R) in fmol/well. Kd and R are calculated based on the presence ofone
binding site. Values represent means+s.e.m. (n). aSignificantly different (P<0.05) vs rhTSH.
bSignificantly different (P<0.05) vs FRTL-5/T.
analysis is only reported for the one class model (Table I).
Neither the KS (1.0-2.4 nM) nor the receptor number (R)
differed significantly among the different cell lines. Competi-
tion by TSH from several species (rat, bovine and
recombinant human) showed a similar pattern between cell
variants (Figure 1). Differences between TSH species were
noted, i.e. the IC50 value of rhTSH was approximately one
order of magnitude higher than the IC50 value of bTSH and
rTSH, by contrast the IC50 value of rTSH did not differ from
IC50 found with bTSH (Table I).
Measurement of cAMP response to TSH (Figure 1, Table II)
The basal intracellular cAMP level was 1 1-fold lower in
FRTL-5/TA cells and 5.8-fold lower in FRTL-5/TP cells than
in wild-type FRTL-5 (1.1 +0.35 pmol cAMP ,ug` DNA). In
contrast a cAMP response was elicited by TSH to the same
maximal level in each cell variant (7.9 -1 1.1 pmol cAMP ig'-l
DNA) by 240 nM. Thus, the induction of cAMP production
by TSH is different between wild-type (10-fold induction) and
the TSH-independent growing cell lines FRTL-5/TP and
FRTL-5/TA (64- to 79-fold induction). Similar EC50 values
were obtained with rTSH and bTSH. The EC50 value of
rhTSH was approximately one order ofmagnitude higher than
the EC50 value of bTSH and rTSH. The significant differences
between rhTSH IC50 and EC50 values, observed in the variant
cell lines, was probably caused by the use of two different
batches of rhTSH. Different batches of rhTSH have different
degrees of sialylation and sulphation, causing different TSH
bioactivity (Szkudlinski et al., 1993).
Northern blotting (Figure 3)
The rat TSH-R-specific probe hybridised with a 5.6 and
3.3 kb mRNA signal respectively, following Northern
blotting. These sizes of mRNA transcripts have been
identified in FRTL-5 cells as transcripts of the rat TSH-R
(Akamizu et al., 1990). In all variants normal sized TSH-R
mRNA transcripts were observed (Figure 3), although the
intensity differed. This was confirmed by densitometry.
Culture of FRTL-5 cells with TSH (6H) down-regulated
TSH-R mRNA and this effect was also demonstrated in
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Figure 2 Scatchard analysis of the competition curve (Figure la)
of FRTL-5 cells (n=7-8).
TSH-dependent FRTL-5/T cells. In FRTL-5/TP and FRTL-
5/TA (TSH-independent variants) the intensity of the TSH-R
transcript was substantially lower in the absence ofTSH (5H)
and stimulation by TSH did not lead to a decreased intensity.
Addition of TSH to culture medium resulted in the
increased expression of c-myc and fos mRNA transcripts,
although the time course and the c-myc/fos mRNA signal
ratio in FRTL-5/TP and FRTL-5/TA differed from that
observed in FRTL-5 wild-type. In FRTL-5 cells bothfos and
c-myc mRNA expression was transiently increased after
40 min of stimulation by TSH, c-myc was still elevated after
24 h. Although the 40 min point is missing, the FRTL-5/T
variant showed the same expression pattern as the FRTL-5/T
cells; myc was elevated at 24 h. In contrast, myc mRNA
expression in FRTL-5/TP and FRTL-5/TA variants was
lower and only slightly influenced by TSH. The expression of
fos was stimulated in the FRTL-5/TP variant after 24 h
stimulation by TSH, in FRTL-5/TA cells after 40 min
stimulation by TSH.
Discussion
In the present study we characterised functional TSH
binding, cAMP response, TSH-R gene expression, and c-
myc/fos proto-oncogene response in rat thyrocytes. As a
model we used stable rat FRTL-5/T, FRTL-5/TP and FRTL-
5/TA thyroid cell lines that spontaneously originated from
wild-type FRTL-5 cells transplanted into nude mice and that
were characterised by TSH-independent growth in combina-
tion with dedifferentiation (Ossendorp et al., 1990). The
functional binding of radiolabelled TSH, characterised by Kd
and number of binding sites, as well as IC50 values of rat
TSH and bovine TSH, were similar between TSH-dependent
(FRTL-5 and T cells) and TSH-independent (TP and TA)
cells. Because of the combination of low-affinity (Kd
101.5 nM) and an exceptionally high number of binding
- 5.6 kb
TSH-R
- 3.3 kb
fos
c-myc
28 S
18 S
Figure 3 Northern blot analysis of TSH-R, fos and c-myc
mRNA in FRTL-5 and variant cells and effect of the presence of
TSH (100MUml-1). 5H, culture without TSH; 6H, culture in the
continuous presence of TSH; 40min and 24h reflect times
following addition of TSH. The experimental protocol used is
described in detail in the Materials and methods.
sites per cells (± 1.1 x 106), we concluded that this class of
low-affinity binding sites represents non-specific binding. This
is in agreement with other reports (Chazenbalk et al., 1990;
Nagayama and Rapoport, 1992), which concluded that this
class of binding sites is an artefact because both untrans-
fected and TSH-R transfected CHO cells show the same low-
affinity site. The FRTL-5/TP and FRTL-5/TA variants
showed normal maximal cAMP response, but 6- to 11-fold
lower basal intracellular cAMP concentrations than wild-type
FRTL-5. The EC50 values obtained with rat and bovine TSH
were similar between all variants and wild-type FRTL-5.
Assays of TSH binding and TSH-induced cAMP production
were carried out under identical conditions of cell culture,
excluding artefacts which might be caused by low-salt and
high-salt culture conditions (Tramontano and Ingbar, 1986).
The present findings therefore formally demonstrate the
dissociation between presence of a functionally intact TSH-
R, able to activate the cAMP cascade and TSH control on
the growth and differentiation in FRTL-5/TP and FRTL-5/
TA cells.
The exact role of TSH in the control of thyroid growth is
still unresolved because thyroid mitogenic and anti-mitogenic
effects have been reported in different species (Maenhaut et
al., 1990; Vassart and Dumont, 1992). TSH is a proven
growth factor in FRTL-5 cells (Jin et al., 1986; Coletta et al.,
1986), dog thyrocytes (Maenhaut et al., 1990) and human
thyrocytes (Dumont et al., 1992). TSH is able to activate
Table II cAMP response to bTSH in FRTL-5 wild type and sublines and EC50 values of different
species of TSH
Cell line
Parameter FRTL-S FRTL-5/T FRTL-S/TP FRTL-S/TA
Basal cAMP 1.1 +0.4 (7) 0.38+0.18a (5) 0.19+0.08b (5) 0.10+O0.03b (6)
Max cAMP 11.1 +2.0 (7) 11.5+3.8 (5) 12.2+3.4 (5) 7.9+2.3 (6)
EC50 bTSH 0.22+0.05c (7) 0.22+0.05c (7) 0.26+0.08c (5) 0.29+0.08c (6)
EC50 rTSH 0.28+0.11c (4) 0.44+0.09cd (4) 0.90+0.80c (3) 0.44+0.16c (3)
EC50 rhTSH 2.1+0.6e (3) 10.1+5.9 (3) 5.8+±1.2f (4) 14.3+1.8 (3)
Max cAMP reflects cAMP production at TSH 240nM, cAMP values are given in pmolig'l DNA,
EC50 values are given in nm, values represent means+s.e.m. (n). aSignificantly different (P<0.05) vs
FRTL-5/TA. bSigmficantly different (P<0.01) vs FRTL-5. cSignificantly different (P<0.05) vs rhTSH.
dSignificantly different (P<0.05) vs bTSH. eSignificantly different (P<0.05) with the other cell variants.
fSignificantly different (P<0.05) vs FRTL-5/TA.
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both the cAMP cascade and phospholipase C pathway
independently by binding to its receptor (Maenhaut et al.,
1990; Fujimoto and Brenner-Gatti, 1992). The current theory
is that enhancement of the cAMP cascade relates to
stimulation and control of functional characteristics in
human and FRTL-5 (rat) thyrocytes, including iodide
uptake and expression of thyroid-specific proteins thyroglo-
bulin and thyroid peroxidase (Maenhaut et al., 1990). In
agreement with this theory is the recent demonstration that
gain-of-function mutations in the TSH-R cause hyperfunc-
tioning thyroid adenomas (Parma et al., 1993) and congenital
hyperthyroidism (Kopp et al., 1995), which are characterised
by higher basal intracellular cAMP concentrations in
agreement with the original report by Kasagi et al. (1980)
in a collection of human adenoma tissues. Dedifferentiating
tumours may then be caused by activation of growth factor
and phorbol ester cascades (Maenhaut et al., 1990; Mockel et
al., 1994), and not through activation of cAMP cascade. The
finding of reduced basal cAMP concentrations in dediffer-
entiated FRTL-5/TP and FRTL-5/TA cells, a factor 6 to 11
lower than FRTL-5 cells, therefore represents novel evidence
to support this theory, and possibly indicates a mechanism of
inverse agonism, causing a reduction in the basal regulation
of the adenylate cyclase (Milligan et al., 1995). FRTL-5/TA
and FRTL-5/TP cells have lost most of the thyroid-specific
phenotype of wild-type FRTL-5 cells as demonstrated by
virtual absence of iodide uptake, and absence of thyroglobu-
lin and TPO mRNA (Ossendorp et al., 1990). In addition,
FRTL-5/TP and FRTL-5/TA cells demonstrate a dissociation
between intact TSH-R function in the cAMP cascade and
loss ofTSH control over thyroid growth. Thus, acquisition of
dominant signal transduction pathways other than the cAMP
cascade, or in theory further downstream in the cAMP
cascade, is relevant and advantageous for thyrocytes to
develop autonomous growth and dedifferentiation.
The present findings do not support the claim by
Berlingeri et al. (1990) that the loss of TSH control on
growth correlates with the complete loss of rat TSH-R gene
expression. Using the same rat TSH receptor cDNA probe,
these authors could not detect TSH-R mRNA in oncogene
transformed FRTL-5 cells; functional TSH binding was not
measured. We detected TSH-R mRNA in TSH-independent
FRTL-5/TP and FRTL-5/TA variants, although the gene
expression was lower than the corresponding transcript signal
in FRTL-5 cells. Interestingly, this reduction in TSH-R gene
expression did not affect the binding characteristics of
radiolabelled TSH. The present data indicated that TSH-R
mRNA does not correspond to the number of functioning
receptors, suggesting: (1) that degradation or stability of
mRNA species (5.6 and 3.3 kb) is different between cell
variants; (2) TSH-R protein may have a larger residence time
on the cell surface; and (3) a functional assay ofTSH binding
needs to be combined with measurement mRNA TSH-R
levels. In the literature, species-specific responses of TSH-R
mRNA expression to TSH exposure have been reported:
down-regulation in rat thyrocytes (Akamizu et al., 1990; and
the present findings), a slight down-regulation in dog
thyrocytes and no marked down-regulation in human
thyrocytes (Maenhaut et al., 1992). Significantly reduced
TSH-R gene expression has also been found in neoplastic
human thyroid tissues in conjunction with reduced thyroglo-
bulin gene expression (Ohta et al., 1990; Elisei et al., 1994).
However, several laboratories have shown that functional
TSH binding is, in general, not different between normal and
neoplastic human thyroid tissues (Karlsson and Dahlberg,
1979; Matsuo et al., 1993). Therefore, a similar discrepancy
as found in FRTL-5/TP and FRTL-5/TA cells between
reduced TSH-R gene expression and intact TSH binding can
exist in human thyroid neoplasms.
Coletta et al. (1986) showed that TSH increasedfos and c-
myc gene expression in FRTL-5 cells under controlled
conditions of thyrocyte growth. Our findings on fos and c-
myc gene expression in FRTL-5 cells are similar to those by
Coletta et al. (1986). and to the findings in dog thyrocytes
(Reuse et al., 1990); fos and c-myc gene expression were
transiently stimulated after the addition ofexogenous TSH to
TSH-deprived FRTL-5 cells or T variant cells. Interestingly,
in TSH-independent FRTL-5/TP and FRTL-5/TA variants
addition of exogenous TSH was again associated with an
increase infos and c-myc gene expression, although the latter
transcript signal was reduced compared with wild-type
FRTL-5. Our data unequivocally show that the TSH-
induced gene expression offos and c-myc can be dissociated
from the phenomenon of TSH-dependent growth and are in
agreement with and extend the conclusion by Heldin and
Westermark (1988) and Wyllie et al. (1989). Other possible
mechanisms, known to activate the thyroid-specific genes Tg,
TPO and TSH-R, are Pax-8 and thyroid transcription factor
1 and 2 (Zannini et al., 1992; Civitareale et al., 1993; Shimura
et al., 1994). Interestingly, transformation of FRTL-5 cells
with viral oncogenes (Ki-ras, Ha-ras and mos) leads to
undetectable expression of Tg and TPO genes (as in the
FRTL-5/TP and FRTL-5/TA variants), in combination with
absence of Pax-8 expression (Francis-Lang et al., 1992).
Further studies are planned to characterise the dominant
signal transduction pathways in FRTL-5/TP and FRTL-5/
TA cells and their effect on genes known to be involved in
thyroid growth and function. In conclusion, a functionally
normal TSH-R was found in FRTL-5 cells and its TSH-
independent variants. Mutations in the TSH-R or G,a are
therefore unlikely explanations for the TSH independence in
FRTL-5/TP and FRTL-5/TA cells. In these cells the
functionally intact TSH-R is dissociated from the TSH
control on growth and differentiation. Supported by the
reduced basal levels of cAMP in FRTL-5/TP (6-fold) and
FRTL-5/TA (11-fold), we conclude that a different mechan-
ism, down-stream of the cAMP cascade, is responsible for a
different activation pattern offos, c-myc and TSH-R mRNA
and the autonomous growth of FRTL-5/TP and FRTL-5/TA
cells.
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